REGN FY 2025 Earnings Report — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

Regeneron Pharmaceuticals, Inc.REGN

FY 2025 Earnings

Reported February 4, 2026

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2025	Prior Q	FY 2024	QoQ Change	YoY Change
Revenue	$14.3B	—	$14.2B	—	1.0%
Op. Income	$3.6B	—	$4.0B	—	-10.3%
Gross Margin	85.4%	—	86.1%	—	-0.8pp
Net Margin	31.4%	—	31.1%	—	0.3pp
EPS (Diluted)	$41.48	—	$38.34	—	8.2%
Free Cash Flow	$4.1B	—	$3.7B	—	11.3%

Revenue Flow

Item	Amount
REVENUE	$14.3B
Cost of Revenue	$2.1B
GROSS PROFIT	$12.2B
R&D Expenses	$5.9B
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$2.7B
Other Expenses	$114M
Operating Expenses	$8.7B
Cost & Expenses	$10.8B
OPERATING INCOME	$3.6B
Interest Income	$717M
Interest Expense	$44M
Other Income/Expenses	$1.7B
INCOME BEFORE TAX	$5.2B
Income Tax Expense	$726M
Net Income from Continuing Ops	$4.5B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$4.5B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$4.5B
D&A	$544M
EBIT	$5.3B
EBITDA	$5.8B
EPS	$43
EPS Diluted	$41

Income Statement

Item	Amount
REVENUE	$14.3B
Cost of Revenue	$2.1B
GROSS PROFIT	$12.2B
R&D Expenses	$5.9B
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$2.7B
Other Expenses	$114M
Operating Expenses	$8.7B
Cost & Expenses	$10.8B
OPERATING INCOME	$3.6B
Interest Income	$717M
Interest Expense	$44M
Other Income/Expenses	$1.7B
INCOME BEFORE TAX	$5.2B
Income Tax Expense	$726M
Net Income from Continuing Ops	$4.5B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$4.5B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$4.5B
D&A	$544M
EBIT	$5.3B
EBITDA	$5.8B
EPS	$43
EPS Diluted	$41

Cash Flow Statement

Item	Amount
Net Income	$4.5B
Depreciation & Amortization	$544M
Stock-Based Compensation	$994M
Deferred Income Tax	-$785M
Other Non-Cash Items	-$811M
Change in Working Capital	$533M
OPERATING CASH FLOW	$5.0B
Capital Expenditure	-$898M
Acquisitions (Net)	-$3M
Purchases of Investments	-$11.0B
Sales/Maturities of Investments	$11.5B
Other Investing Activities	-$315M
NET CASH FROM INVESTING	-$629M
Net Debt Issuance	$0
Common Stock Repurchased	-$3.4B
Common Dividends Paid	-$370M
Other Financing Activities	-$542M
NET CASH FROM FINANCING	-$3.7B
FREE CASH FLOW	$4.1B
Net Change in Cash	$635M

Balance Sheet

Item	Amount
Cash & Equivalents	$3.1B
Short-Term Investments	$5.5B
Net Receivables	$5.7B
Inventory	$3.2B
Other Current Assets	$475M
TOTAL CURRENT ASSETS	$18.0B
PP&E (Net)	$5.1B
Goodwill	$0
Intangible Assets	$1.3B
Long-Term Investments	$10.3B
Tax Assets	$4.1B
Other Non-Current Assets	$1.8B
TOTAL NON-CURRENT ASSETS	$22.5B
TOTAL ASSETS	$40.6B
Account Payables	$939M
Short-Term Debt	$0
Deferred Revenue	$553M
Other Current Liabilities	$0
TOTAL CURRENT LIABILITIES	$4.4B
Long-Term Debt	$2.0B
Deferred Revenue NC	$209M
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$2.0B
TOTAL NON-CURRENT LIABILITIES	$4.9B
TOTAL LIABILITIES	$9.3B
Common Stock	$100.0K
Additional Paid-In Capital	$14.0B
Retained Earnings	$35.8B
Treasury Stock	-$18.6B
Accum. Other Comp. Income	$78M
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$31.3B
Minority Interest	$0
TOTAL EQUITY	$31.3B
TOTAL LIABILITIES & EQUITY	$40.6B
Total Debt	$2.7B
Net Debt	-$412M